An Improved Procedure for the Preparation of Poziotinib

Cai Zhi-qiang, Wei‐Ying Ma, Xu Hou2015 · DOI

Abstract: Objective: To improve the synthetic procedure of the anticancer drug poziotinib. Methods: Poziotinib was synthesized in six stages starting from 7-methoxy-4-oxo-3,4-dihydroquinazolin-yl acetate (2) via chlorination, amination, hydrolysis, condensation, deprotection of Boc, and amidation reactions. Compound 2 reacted with POCl₃ followed by reaction with 3,4-dichloro-2-fluoroaniline to afford intermediate 8. Compound 8 reacted with aqueous ammonia in methanol to obtain 9, which then underwent a condensation reaction to obtain 6. Compound 6 was deprotected using CF₃COOH followed by an amidation reaction with acryloyl chloride to afford poziotinib. Results: The anticancer drug poziotinib was synthesized in 6 steps with an overall yield of 37.2%. The structures were characterized by ¹H NMR and ESI-MS. Conclusion: The starting material is easily accessible, reaction conditions are moderate, and the operation is convenient. The reaction steps are shortened, making this method suitable for industrial production.

Introduction

Poziotinib is a high-potential drug for treating non-small cell lung cancer (NSCLC), as well as breast and gastric cancers. It functions as an irreversible inhibitor of the epidermal growth factor receptor (EGFR) family (HER1, HER2, and HER4), making it particularly effective against tumors with specific mutations that resist earlier generations of treatment.

However, the original synthetic route reported in 2008 is poorly suited for large-scale manufacturing. This "medicinal chemistry" approach relied on expensive reagents like anhydrous ammonia in methanol (NH₃/MeOH) and required complex chromatographic column separations to purify key intermediates. These factors drive up costs and increase hazardous waste generation. This study presents a streamlined, six-step "process chemistry" solution that utilizes cheaper materials, moderate conditions, and simpler purification methods like filtration, achieving a 37.2% overall yield.

Synthetic Methodology

The researchers proposed an alternate six-stage route starting from the relatively inexpensive material 7-methoxy-4-oxo-3,4-dihydroquinazolin-yl acetate (2). The optimized pathway is illustrated below:

Optimized synthetic route for Poziotinib (1) starting from compound 2.

Reaction Stages:

  1. Chlorination and Amination: Compound 2 is reacted with POCl₃ and Et₃N to form intermediate 3, which is then reacted with 3,4-dichloro-2-fluoroaniline to yield intermediate 8.
  2. Hydrolysis: Intermediate 8 is converted into the phenol derivative 9 using an aqueous ammonia solution.
  3. Condensation: Intermediate 9 reacts with tert-butyl 4-(tosyloxy)piperidin-1-carboxylate to form the key intermediate 6.
  4. Deprotection and Final Amidation: The Boc protecting group is removed from intermediate 6 using trifluoroacetic acid (CF₃COOH) to yield 7, which finally reacts with acryloyl chloride to produce Poziotinib (1).

Optimization and Results

A critical part of the process improvement involved optimizing the chlorination of compound 2 to compound 3. The team tested various reagents, including SOCl₂, PCl₃, and POCl₃, under different conditions.

Optimization of the chlorination step (conversion of 2 to 3) using various reagents.

As shown in the data, while SOCl₂ and PCl₃ resulted in slow reactions and poor conversion, the combination of POCl₃ with Et₃N (Entry 3) achieved a 95% conversion rate in just 2 hours at 80 °C.

Beyond reagent optimization, the most significant advancement for industrial viability is the elimination of column chromatography. By designing the synthesis so that intermediates can be purified through precipitation and filtration followed by washing with common solvents (like isopropanol or methanol/water), the process becomes significantly more scalable.

Key Yields:

  • Intermediate 8: 94.6%
  • Intermediate 9: 88.1%
  • Intermediate 6: 74.3%
  • Overall Process Yield: 37.2%

The final Poziotinib product was obtained as a white powder, with its structure confirmed via ¹H NMR and mass spectrometry (m/z: 491 [M + H]⁺).

Conclusion

This improved synthetic procedure for Poziotinib offers a practical pathway for industrial production. By utilizing a strategic starting point and optimizing reaction conditions to favor filtration over chromatography, the researchers have developed a method that is cost-effective, efficient, and yields a high-purity product. Future work may focus on further "greening" the process through solvent recycling and optimizing the condensation step to further increase the overall yield.

Summary updated

Abstract

Objective: To improve the synthetic procedure of the anticancer drug poziotinib. 2. Methods: The poziotinib was synthesized in six stages starting from 7-methoxy-4-oxo-3,4-dihydroquinazolin-yl acetate (2) by chlorinated, ammonification, hydrolysis, condensation, take off Boc and amidation reaction. Compound 2 reacted with POCl3 followed by ammonification to afford 8. Compound 8 reacted with ammonia water in methanol to obtain 9 which passes through the condensation reaction to obtain 6. Compound 6 took off Boc in the CF3COOH followed by amidation reaction to afford the poziotinib. Results: The anticancer drug poziotinib was synthesized by using 7methoxy-4-oxo-3,4-dihydroquinazolin-yl acetate as starting material in 6 steps. The structures were characterized by 1H NMR and ESI-MS. 4. Conclusion: The starting material is very easy to get, the reaction conditions are moderate and the operation is convenient. The reaction steps are shortened and the overall yield is 37.2 %. This method is suitable for industrial producing.
BibTeX
@misc{zhiqiang2015improved,
  author = {Cai Zhi-qiang and Wei‐Ying Ma and Xu Hou},
  title = {{An Improved Procedure for the Preparation of Poziotinib}},
  year = {2015},
  doi = {10.2991/meic-15.2015.176},
}
Figure